EMA accepts regulatory submission for Takeda’s dengue vaccine candidate
The submission is the first in a series that will…
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.